Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Melanoma 9Recurrence 2Brain Neoplasms 2Squamous Cell Carcinoma of Head and Neck 1Neoplasms 1Neoplasm Metastasis 1Lymphoma 1Locally Advanced Melanoma 1Diabetes Mellitus, Insulin-Dependent, 12 1Central Nervous System Neoplasms 1Carcinoma, Merkel Cell 1Carcinoma, Basal Cell 1

Interventions

Cisplatin 168Radiotherapy 110pembrolizumab 96Cetuximab 95Docetaxel 74Carboplatin 74Radiotherapy, Intensity-Modulated 55Paclitaxel 51Nivolumab 50Fluorouracil 47Surgical Procedures, Operative 28Radiation 26Magnetic Resonance Spectroscopy 25durvalumab 23Drug Therapy 23Radiosurgery 21Biopsy 19Albumin-Bound Paclitaxel 19130-nm albumin-bound paclitaxel 18Taxes 17tislelizumab 16toripalimab 15Chemoradiotherapy 15Neoadjuvant Therapy 14Erlotinib Hydrochloride 14Blood Specimen Collection 14camrelizumab 13Immunohistochemistry 13Specimen Handling 12tremelimumab 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Squamous Cell Carcinoma of Head and Neck × Opdualag × Clear all
NCT04326257 2026-01-08

Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy

University of Pittsburgh

Phase 2 Completed
20 enrolled 13 charts
Head & Neck

Diabetes Mellitus, Insulin-Dependent, 12, Squamous Cell Carcinoma of Head and Neck, Neoplasm Metastasis, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡